GFT505 80mg + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Atherogenic Dyslipidaemia

Conditions

Atherogenic Dyslipidaemia, Abdominal Obesity

Trial Timeline

Jan 1, 2009 → Nov 1, 2009

NCT ID

NCT01271751

About GFT505 80mg + Placebo

GFT505 80mg + Placebo is a phase 2 stage product being developed by Genfit for Atherogenic Dyslipidaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01271751. Target conditions include Atherogenic Dyslipidaemia, Abdominal Obesity.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01271777	Phase 2	Completed	Jan 1, 2011	Nov 1, 2011	Insulin Resistance
NCT01261494	Phase 2	Completed	Dec 1, 2010	Jun 1, 2011	Type II Diabetes Mellitus
NCT01275469	Phase 2	Completed	Jun 1, 2009	Jan 1, 2010	Impaired Glucose Tolerance
NCT01271751	Phase 2	Completed	Jan 1, 2009	Nov 1, 2009	Atherogenic Dyslipidaemia

Other Products from Genfit

Elafibranor + PlaceboPhase 3

VS-01 on top of SOCPhase 2

elafibranor 120mg + PlaceboPhase 2

GFT505 80mg + PlaceboPhase 2

Elafibranor 80mg + Elafibranor 120mgPhase 2